9th Annual Biomarkers Congress

Wyeth presents Pristiq data

Wyeth is revealing more Pristiq data today from two Phase III clinical studies of Pristiq. Earlier this year, the FDA issued an approvable letter for Pristiq, delaying the launch of the drug for major depressive disorder. The data showed that patients who received a 50 mg/day dose of the drug for MDD experienced a statistically significant reduction in the symptoms of major depression compared to placebo.

Fierce Biotech

http://www.fiercebiotech.com/story/wyeth-presents-pristiq-data/2007-12-12



Comments

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.